Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Systemic Therapy in Early HER2+ Breast Cancer: More Benefit w/Neoadjuvant Trastuzumab/Pertuzumab/Docetaxel Therapy, Adjuvant Trastuzumab Improves DFS and OS

0 views
December 4, 2019
Comments 0
Login to view comments. Click here to Login